There is now conclusive and reassuring evidence of the cannnabis-based treatment Sativex’s tolerability and effectiveness in reducing spasticity and related symptoms in multiple sclerosis, according ...

Sativexâ Approved in New Zealand for the Treatment of Spasticity due to Multiple Sclerosis Porton Down, UK, 3 November 2010: GW Pharmaceuticals plc (AIM: GWP) today announces that the New Zealand ...

Spasticity is a condition that affects your voluntary muscles and impacts your movement. There are different kinds of muscles problems that can affect different limbs. This condition can happen in ...

GW Pharmaceuticals has kicked off a Phase III trial of Sativex in multiple sclerosis spasticity, data from which should form the basis of the drug’s planned resubmission in Europe in 2008. GW ...

Sativexâ Approved in New Zealand for the Treatment of Spasticity due to Multiple Sclerosis Porton Down, UK, 3 November 2010: GW Pharmaceuticals plc (AIM: GWP) today announces that the New Zealand ...

For many individuals living with multiple sclerosis (MS), muscle spasticity, an often painful and limiting symptom, can be one of the most persistent and frustrating aspects of the disease.

XenoPort, Inc. announced that it had reached agreement with the US Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for a pivotal phase 3 clinical trial of arbaclofen ...

Medicinal cannabinoids are helpful for treatment of spasticity, pain, and bladder dysfunction for patients with multiple sclerosis (MS), although their efficacy is "limited," new research suggests.

Dec. 5 -- FRIDAY, Dec. 4 (HealthDay News) -- Cancer patients, glaucoma patients and others can benefit from medical marijuana, and now a new analysis shows that it can help multiple sclerosis (MS) ...

The spasticity treatment pipeline is rapidly evolving to meet the need for safer, longer-lasting, and more targeted therapies. Common in conditions like cerebral palsy, MS, stroke, and spinal injuries ...